AI Article Synopsis

  • Cyclin G1 is a gene responsive to p53 and is induced in cells under ARF arrest, but its function in growth regulation is not fully understood.
  • Cyclin G1 interacts with ARF, Mdm2, and p53 and can induce a halt in G(1)-phase cell growth at high levels, linked to p53 activation.
  • While high levels of cyclin G1 inhibit growth, lower levels can enhance ARF's growth arrest effect, and its regulation involves degradation by Mdm2, indicating a complex role in tumor suppression pathways involving p53 and pRb.

Article Abstract

Cyclin G1 is a p53-responsive gene that is induced in alternative reading frame (ARF)-arrested cells, yet its role in growth control is unclear. We tested its effects on growth and involvement in the ARF-Mdm2-p53 tumor suppressor pathway. We show that cyclin G1 interacts with ARF, Mdm2, and p53 in vitro and in vivo. At high levels, cyclin G1 induces a G(1)-phase arrest in mammalian cells that coincides with p53 activation. Conversely, lower levels of cyclin G1 lack intrinsic growth inhibitory effects yet potentiate ARF-mediated growth arrest. Notably, cyclin G1 is down-regulated by Mdm2 through proteasome-mediated degradation. These data suggest that cyclin G1 is a positive feedback regulator of p53 whose expression is restrained by Mdm2. Interestingly, growth inhibition by cyclin G1 does not require p53 but instead exhibits partial retinoblastoma protein (pRb) dependence. These findings reveal that cyclin G1 has growth inhibitory activity that is mechanistically linked to ARF-p53 and pRb tumor suppressor pathways.

Download full-text PDF

Source

Publication Analysis

Top Keywords

growth inhibitory
12
tumor suppressor
12
cyclin
9
cyclin growth
8
inhibitory activity
8
prb tumor
8
suppressor pathways
8
levels cyclin
8
growth
6
activity linked
4

Similar Publications

Trophoblast cell-surface antigen 2 (TROP 2) has re-emerged as a promising biomarker in triple-negative breast cancer (TNBC), with high overexpression in many TNBC cases. However, despite its potential and approval as an antibody-drug-conjugate for TNBC treatment, TROP 2-targeted delivery systems are currently underexplored. Therefore, this study was aimed at exploiting the potential of TROP 2 targeting by encapsulating metformin (Met), an antidiabetic drug associated with tumor growth inhibitory properties, inside liposomes decorated with TROP 2-targeting single-chain variable fragments (scFvs).

View Article and Find Full Text PDF

This study reports on the facile development of star-shaped gold nanoparticles via seed-mediated growth protocol. Gold nanostars (AuNSTs) demonstrated average particle size of 48 nm using transmission electron microscopy (TEM). Chemical composition of AuNSTs was verifired using energy dispersive X-ray spectroscopy (EDX) mapping.

View Article and Find Full Text PDF

Mycoplasma (M.) hyosynoviae is a facultative pathogen, causing arthritis in finisher pigs world-wide. In the absence of a commercial vaccine improvement of housing conditions and antibiotic therapy are the only options to alleviate the clinical signs.

View Article and Find Full Text PDF

Developmental and epileptic encephalopathies (DEEs), a class of devastating neurological disorders characterized by recurrent seizures and exacerbated by disruptions to excitatory/inhibitory balance in the brain, are commonly caused by mutations in ion channels. Disruption of, or variants in, were implicated as causal for a set of DEEs, but the underlying mechanisms were clouded because is expressed in both excitatory and inhibitory neurons, undergoes extensive alternative splicing producing multiple isoforms with distinct functions, and the overall roles of FGF13 in neurons are incompletely cataloged. To overcome these challenges, we generated a set of novel cell-type-specific conditional knockout mice.

View Article and Find Full Text PDF

Chemotherapeutic agents are widely used to combat breast cancer. However, due to their non-selective biodistribution, their usage is associated with severe adverse effects on healthy tissues. In this study, a chitosan-stabilized nanoemulsion (CSNE) was prepared for the codelivery of curcumin (CUR) and methotrexate (MTX).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!